Institution
Moncton Hospital
Healthcare•Moncton, New Brunswick, Canada•
About: Moncton Hospital is a healthcare organization based out in Moncton, New Brunswick, Canada. It is known for research contribution in the topics: Durvalumab & Tremelimumab. The organization has 91 authors who have published 135 publications receiving 3639 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Ipilimumab shows activity in advanced melanoma, with encouraging survival and manageable adverse events, and budesonide should not be used prophylactically for grade ≥2 diarrhea associated with ipilimumAB therapy.
Abstract: Purpose: Diarrhea (with or without colitis) is an immune-related adverse event (irAE) associated with ipilimumab. A randomized, double-blind, placebo-controlled, multicenter, multinational phase II trial was conducted to determine whether prophylactic budesonide (Entocort EC), a nonabsorbed oral steroid, reduced the rate of grade ≥2 diarrhea in ipilimumab-treated patients with advanced melanoma. Experimental Design: Previously treated and treatment-naive patients ( N = 115) with unresectable stage III or IV melanoma received open-label ipilimumab (10 mg/kg every 3 weeks for four doses) with daily blinded budesonide (group A) or placebo (group B) through week 16. The first scheduled tumor evaluation was at week 12; eligible patients received maintenance treatment starting at week 24. Diarrhea was assessed using Common Terminology Criteria for Adverse Events (CTCAE) 3.0. Patients kept a diary describing their bowel habits. Results: Budesonide did not affect the rate of grade ≥2 diarrhea, which occurred in 32.7% and 35.0% of patients in groups A and B, respectively. There were no bowel perforations or treatment-related deaths. Best overall response rates were 12.1% in group A and 15.8% in group B, with a median overall survival of 17.7 and 19.3 months, respectively. Within each group, the disease control rate was higher in patients with grade 3 to 4 irAEs than in patients with grade 0 to 2 irAEs, although many patients with grade 1 to 2 irAEs experienced clinical benefit. Novel patterns of response to ipilimumab were observed. Conclusions: Ipilimumab shows activity in advanced melanoma, with encouraging survival and manageable adverse events. Budesonide should not be used prophylactically for grade ≥2 diarrhea associated with ipilimumab therapy. (Clin Cancer Res 2009;15(17):5591–8)
528 citations
••
TL;DR: The number of comorbidities predicted the presence of pain at 24 months follow-up and, for the first time, preoperative PCS scores were shown to predict chronic postoperative pain.
Abstract: BACKGROUND: Pain is the primary indication for both primary and revision total knee arthroplasty (TKA); however, most arthroplasty outcome measures do not take pain into account.
255 citations
•
TL;DR: More widespread use of multiple nonantibiotic modalities of treatment for infected chronic wounds and rational antibiotic prescribing should reduce the risk of future antimicrobial resistance such as MRSA.
Abstract: Chronic wounds all have bacterial contamination, which will not impair healing. Wound contamination must be distinguished from wound colonization and infection. Bacterial infection in wounds depends on the number of organisms present, their virulence, and host resistance. The most important indicators of infection are both local and systemic host characteristics and a holistic assessment of the patient. Several specimen collection and culture techniques are available to measure bacterial burden in the chronic wound. Advantages and disadvantages of each one discussed along with a rational approach to systemic antibiotic therapy. The presence of foreign material such as skin grafts or skin substitutes may lower the bacterial burden that may impair healing from 1.0 x 10(6) colony-forming units to 1.0 x 10(5) or less. The benefits of wound debridement, wound irrigation, and local nonantibiotic modes of treatment have been proven but the use of topical antibiotics and antiseptics requires further assessment. More widespread use of multiple nonantibiotic modalities of treatment for infected chronic wounds and rational antibiotic prescribing should reduce the risk of future antimicrobial resistance such as MRSA.
255 citations
••
TL;DR: Tolevamer, a novel polystyrene binder of C. difficile toxins A and B, effectively treats mild to moderate C.difficile diarrhea and merits further clinical development.
Abstract: BACKGROUND Current antibiotic therapies for Clostridium difficile-associated diarrhea have limitations, including progression to severe disease, recurrent C. difficile-associated diarrhea, and selection for nosocomial pathogens. Tolevamer, a soluble, high-molecular weight, anionic polymer that binds C. difficile toxins A and B is a unique nonantibiotic treatment option. METHODS In this 3-arm, multicenter, randomized, double-blind, active-controlled, parallel-design phase II study, patients with mild to moderately severe C. difficile-associated diarrhea were randomized to receive 3 g of tolevamer per day (n = 97), 6 g of tolevamer per day (n = 95), or 500 mg of vancomycin per day (n = 97). The primary efficacy parameter was time to resolution of diarrhea, defined as the first day of 2 consecutive days when the patient had hard or formed stools (any number) or < or = 2 stools of loose or watery consistency. RESULTS In the per-protocol study population, resolution of diarrhea was achieved in 48 (67%) of 72 patients receiving 3 g of tolevamer per day (median time to resolution of diarrhea, 4.0 days; 95% confidence interval, 2.0-6.0 days), in 58 (83%) of 70 patients receiving 6 g of tolevamer per day (median time to resolution of diarrhea, 2.5 days; 95% confidence interval, 2.0-3.0 days), and in 73 (91%) of 80 patients receiving vancomycin (median time to resolution of diarrhea, 2.0 days; 95% confidence interval, 1.0-3.0 days). Tolevamer administered at a dosage of 6 g per day was found to be noninferior to vancomycin administered at a dosage of 500 mg per day with regard to time to resolution of diarrhea (P = .02) and was associated with a trend toward a lower recurrence rate. Tolevamer was well tolerated but was associated with an increased risk of hypokalemia. CONCLUSIONS Tolevamer, a novel polystyrene binder of C. difficile toxins A and B, effectively treats mild to moderate C. difficile diarrhea and merits further clinical development.
219 citations
••
University of Texas Health Science Center at Houston1, Spanish National Research Council2, University of Texas MD Anderson Cancer Center3, University College London4, North Shore-LIJ Health System5, Autonomous University of Madrid6, Autonomous University of Barcelona7, University of Groningen8, Karolinska Institutet9, University of Granada10, Oklahoma Medical Research Foundation11, University of Queensland12, University of Milan13, Charité14, Hannover Medical School15, University of Cologne16, University of Erlangen-Nuremberg17, VU University Amsterdam18, Leiden University19, Lund University20, University of Verona21, University of Glasgow22, Newcastle University23, University of Manchester24, Johns Hopkins University25, Northwestern University26, McGill University27, University of Western Ontario28, University of California, Los Angeles29, University of Michigan30, University of Minnesota31, Medical University of South Carolina32, Georgetown University33, Boston University34, University of Alabama at Birmingham35, University of Utah36, Carolinas Healthcare System37, Moncton Hospital38, Alberta Health Services39, McMaster University40, University of Saskatchewan41, University of Manitoba42, Utrecht University43, Radboud University Nijmegen44
TL;DR: This study has increased the number of known genetic associations with SSc, provided further insight into the pleiotropic effects of shared autoimmune risk factors, and highlighted the power of dense mapping for detecting previously overlooked susceptibility loci.
Abstract: In this study, 1,833 systemic sclerosis (SSc) cases and 3,466 controls were genotyped with the Immunochip array. Classical alleles, amino acid residues, and SNPs across the human leukocyte antigen (HLA) region were imputed and tested. These analyses resulted in a model composed of six polymorphic amino acid positions and seven SNPs that explained the observed significant associations in the region. In addition, a replication step comprising 4,017 SSc cases and 5,935 controls was carried out for several selected non-HLA variants, reaching a total of 5,850 cases and 9,401 controls of European ancestry. Following this strategy, we identified and validated three SSc risk loci, including DNASE1L3 at 3p14, the SCHIP1-IL12A locus at 3q25, and ATG5 at 6q21, as well as a suggested association of the TREH-DDX6 locus at 11q23. The associations of several previously reported SSc risk loci were validated and further refined, and the observed peak of association in PXK was related to DNASE1L3. Our study has increased the number of known genetic associations with SSc, provided further insight into the pleiotropic effects of shared autoimmune risk factors, and highlighted the power of dense mapping for detecting previously overlooked susceptibility loci.
177 citations
Authors
Showing all 91 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ross Leighton | 31 | 75 | 3915 |
Laura Gaudet | 19 | 61 | 1133 |
Hazem I. Assi | 14 | 71 | 1369 |
Peter Docherty | 13 | 16 | 707 |
Brendan Kenny | 9 | 9 | 351 |
Roderick Canning | 9 | 22 | 580 |
Daniel Smyth | 8 | 13 | 212 |
Carolyn Baer | 8 | 8 | 260 |
Mahmoud Abdelsalam | 5 | 9 | 89 |
Michael E. Forsythe | 4 | 8 | 436 |
Franzjosef Schweiger | 4 | 6 | 69 |
Sylvia Gautreau | 4 | 6 | 22 |
Mohammed Harb | 4 | 8 | 130 |
Sheldon H. Rubin | 4 | 7 | 122 |
M. Kuhn | 3 | 3 | 151 |